Benzoyl Peroxide
| Evidence Level: L5 | Predicted Indications: 4 |
Table of Contents
- Benzoyl Peroxide
- Pharmacist Assessment Report
- Benzoyl Peroxide: topical oxidising keratolytic and antibacterial agent → vulvar inverted follicular keratosis
- One-Sentence Summary
- Quick Overview
- Why is This Prediction Reasonable?
- Clinical Trial Evidence
- Literature Evidence
- Australia Market Information
- Safety Considerations
- Conclusion and Next Steps
- Disclaimer
Benzoyl Peroxide: topical oxidising keratolytic and antibacterial agent → vulvar inverted follicular keratosis
One-Sentence Summary
Benzoyl peroxide is a topical agent used on the skin, here marketed in Australia as a gel. The TxGNN model predicts it may be relevant to vulvar inverted follicular keratosis, but no clinical trials and no publications directly study this condition, so the prediction rests on model output alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | vulvar inverted follicular keratosis |
| TxGNN Prediction Score | 0.9992 |
| Evidence Level | L5 |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data are not available for this drug. Benzoyl peroxide is generally understood to act as a topical keratolytic and comedolytic agent with antibacterial activity against Cutibacterium acnes, and these actions could plausibly influence follicular keratinisation.
Inverted follicular keratosis is a benign follicular lesion that is closely related to seborrhoeic keratosis. The very high TxGNN score probably reflects this closeness to conditions already associated with the drug, rather than independent evidence. No mechanism specific to this lesion has been established, and the link cannot be assessed further without mechanism data.
Vulvar skin and mucosa are sensitive, so irritation from a topical oxidising agent is also a practical concern at this site.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available for vulvar inverted follicular keratosis.
Australia Market Information
| ARTG Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| ARTG 13363H | Epiduo | Gel 1 mg-25 mg per g, 30 g | Not recorded in the local data |
Safety Considerations
Specific warnings and contraindications from the approved label are not available in the data compiled for this report. Please refer to the TGA-approved Product Information (PI) for safety information.
Drug interaction searches returned no recorded interactions.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is supported only by a model score (0.9992), with no trials or publications on this condition (Evidence Level L5). The label safety data and mechanism data are also missing, and vulvar irritation is a plausible concern.
To proceed, the following is needed:
- Mechanism of action data for the drug
- Published case series or studies on treating vulvar inverted follicular keratosis
- Label warnings and contraindications from the TGA Product Information
- Assessment of vulvar tolerability for a topical oxidising agent
- Clarification of the approved indication from the licence records
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.